Unresectable pancreatic carcinoma: Correlating length of survival with choice of palliative bypass

Citation
La. Di Fronzo et al., Unresectable pancreatic carcinoma: Correlating length of survival with choice of palliative bypass, AM SURG, 65(10), 1999, pp. 955-958
Citations number
14
Categorie Soggetti
Surgery
Journal title
AMERICAN SURGEON
ISSN journal
00031348 → ACNP
Volume
65
Issue
10
Year of publication
1999
Pages
955 - 958
Database
ISI
SICI code
0003-1348(199910)65:10<955:UPCCLO>2.0.ZU;2-7
Abstract
The preferred method of biliary bypass and the need for prophylactic gastro enterostomy in unresectable pancreatic carcinoma are dependent on the lengt h of survival of the patient. From 1980 through 1996, 60 patients with biop sy-proven pancreatic cancer were found to be unresectable at exploration. T he reasons for unresectability included major vascular involvement in 21 pa tients (35%), liver metastases in 16 (26.7%), celiac or portal lymph node m etastases in 13 (21.7%), carcinomatosis in 5 (8.3%), and advanced age and/o r comorbid medical condition in 4 patients (6.7%). One patient refused panc reaticoduodenectomy. Nine patients (15%) underwent Roux-en-Y choledochojeju nostomy, and 51 (85%) underwent choledochoduodenostomy. Prophylactic gastro enterostomy was not performed routinely; however, in 9 patients (15%), gast rojejunostomy was performed for impending duodenal obstruction. Late biliar y obstruction did not occur. Late gastric obstruction occurred in 6 of 51 p atients (11.7%), at a median of 13.5 months after initial operation (range, 5-26 months). However, late gastric obstruction primarily occurred in 5 of 31 patients (16%) with locally advanced disease (major vessel involvement or lymph node metastases). The median survival was 12.0 months (range, 3.5- 62 months) for patients with major vessel involvement, 11.5 months (range, 3-42 months) for patients with lymph node metastases, 4.5 months (range 0.5 -24 months) for patients with liver metastases, 5.0 months (range, 4-7 mont hs) for patients with carcinomatosis, and 9.0 months (range 2-27 months) fo r patients with significant comorbid medical illness and/or advanced age. P atients with liver metastases and carcinomatosis do not survive long enough to develop late obstruction. On the other hand, patients with locally adva nced pancreatic carcinoma have a longer median survival and could be consid ered for prophylactic gastroenterostomy to avoid late gastric obstruction. Choledochoduodenostomy offers effective palliation for biliary obstruction.